Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej

Blood (2019) 134 (Supplement_1): 2791.

https://doi.org/10.1182/blood-2019-122974

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Blood (2019) 134 (Supplement_1): 170.

https://doi.org/10.1182/blood-2019-125488

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 355.

https://doi.org/10.1182/blood-2019-123930

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Blood (2019) 134 (Supplement_1): 400.

https://doi.org/10.1182/blood-2019-124017

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP

Blood (2019) 134 (Supplement_1): 4318.

https://doi.org/10.1182/blood-2019-123057

Published: 2019

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 185.

https://doi.org/10.1182/blood-2018-99-117050

Published: 2018

Journal Articles

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Meaghan Wall, MBBS, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2018-99-113905

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Jianan Gong, PhD, Rachel Thijssen, Richard W Birkinshaw, PhD, Ella Thompson, PhD, Charis E Teh, PhD, Tamia Nguyen, Zhen Xu, PhD, Christoffer Flensburg, PhD, Thomas Lew, MBBS, Ian Majewski, PhD, Daniel Gray, David Alan Westerman, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, John F. Seymour, MBBS, PhD, Peter E Czabotar, PhD, David Huang, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): LBA-7.

https://doi.org/10.1182/blood-2018-120761

Published: 2018

Journal Articles

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Matthew S. Davids, MD, Andrew W. Roberts, MBBS, PhD, William G. Wierda, MD PhD, Kathryn Humphrey, Debbie J Alter, RN, BSN, Abdullah Masud, PhD, Eike C. Buss, MD, Maria E. Verdugo, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2018-99-117210

Published: 2018

Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2018-99-114048

Published: 2018

NARROW

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only